Objective: Dopamine administration results in variable effects on blood pressure in hypotensive preterm infants. The clinical benefits of dopamine administration in increasing cerebral blood flow (CBF) and reducing adverse neurological outcomes in hypotensive preterm neonates are unclear. The objective of this study was to examine the efficacy of dopamine for treatment of hypotension and investigate the changes in cerebral hemodynamics and central nervous system injury in hypotensive preterm infants following dopamine administration.
Introduction
Although a causal relationship has yet to be established, one variable associated with increased mortality, intraventricular hemorrhage, periventricular leukomalacia and neurodevelopmental morbidity in the preterm infant is systemic hypotension. [1] [2] [3] [4] The normal physiologic range of blood pressure in the preterm infant is not known, 5 necessitating the formulation of a working definition of hypotension by researchers and clinicians. The most frequently used definition of systemic hypotension in preterm neonates in clinical research is a mean blood pressure below the fifth or tenth percentile of the normative data for the infant's gestational and postnatal age and/or weight. 6 The definition used most often in clinical practice for the first 1 to 2 postnatal days is a mean blood pressure less than or equal to the patient's gestational age in weeks. As several studies have shown an association between systemic hypotension and end-organ damage, the overarching goal of the treatment of systemic hypotension is to maintain adequate organ perfusion. The brain of the preterm infants is particularly vulnerable to decreases in perfusion pressure, and many studies have found that hypotension is associated with increased brain injury and poor neurodevelopmental outcome. 7 In addition, studies have shown that increases in blood pressure are associated with increases in cerebral blood flow (CBF) in preterm infants treated with dopamine or epinephrine for the clinical diagnosis of hypotension. 8, 9 Standard empiric treatment for systemic hypotension includes volume expansion, administration of vasopressor/inotropes (for example, dopamine, epinephrine) and/or inotropes (for example, dobutamine). 5, 10 Dopamine is the vasopressor/inotrope most commonly used to treat systemic hypotension in the preterm neonate. 10 The increase in systemic blood pressure following dopamine administration is thought to be a result of arterial vasoconstriction and increased cardiac output. 11 The efficacy of dopamine administration in comparison with other commonly used therapies remains uncertain.
The effect of dopamine on CBF has been the subject of recent research, however, no consensus has been reached regarding the efficacy or safety of dopamine administration for this purpose. 8, 12 As the resolution of hypotension following dopamine administration is in part because of a dose-dependent vasoconstrictor effect, it is possible that deleterious effects in organs may develop during the treatment with dopamine because of decreased organ blood flow and thus oxygen delivery. These effects would be compounded by the already inadequate perfusion of vital and non-vital organs resulting from the hypotensive state. Furthermore, administration of any type of vasopressor may result in sudden uncontrolled increases in blood pressure, which may then lead to central nervous system damage in general and peri-intraventricular hemorrhage in particular. 13 Indeed, recent findings of a retrospective study in very preterm neonates suggest that, as long as adequate tissue perfusion is present, blood pressure below the clinically accepted lower limit of normal blood pressure range during the first postnatal days may not require intervention 14 The investigators reason that the spontaneous increase in blood pressure during the first 24 to 72 h and the risks associated with the use of vasoactive medications may outweigh the potential harm associated with lower perfusion pressures as long as no indirect or direct evidence of decreased systemic and organ blood flow is present.
14 However, it needs to be emphasized that the extent to which the adverse neurologic outcomes associated with hypotension in the preterm neonate treated with vasoactive agents result from preexisting hypotension, the side effects of medications, the uncontrolled fluctuations in blood pressure in the presence of impaired CBF autoregulation 8 and/or represent the natural morbidity in the vulnerable hypotensive preterm neonate, remains unclear. 15 The purpose of this study is to provide a quantitative review of the research examining the relationship between dopamine administration, hypotension, CBF and adverse neurological outcomes, through the use of meta-analytic techniques. CBF changes following dopamine administration in normotensive preterm neonates are also examined in order to provide a comparison of the dopaminergic response of the hemodynamically stable preterm infant to that of its hemodynamically compromised counterpart.
The following five specific hypotheses were examined:
(1) Dopamine administration significantly increases blood pressure in the hypotensive preterm infant. (2) The efficacy of dopamine administration in increasing blood pressure is greater than the efficacy of other forms of therapy for the treatment of hypotension in the preterm infant. (3) Dopamine administration is associated with increased CBF in the hypotensive preterm infant. (4) The increase in CBF following dopamine administration is greater in the hypotensive preterm infant than in the normotensive preterm infant because of the differences in the functional integrity of CBF autoregulation between the two groups. (5) Dopamine administration is associated with an incidence of adverse neurological outcomes similar to the incidence of adverse neurological outcomes associated with other forms of therapy for hypotension in the preterm infant.
Methods

Data sources
Ovid Medline, EBM-Cochrane Database of Systematic Reviews, EBM-Cochrane Central Register of Controlled Trials and EBMDatabase of Abstracts of Reviews of Effects were used to search for all studies examining dopamine administration for the treatment of hypotension in preterm infants. Ancestry search techniques were used to further identify studies (that is, as studies were obtained, references were examined for other possible studies to include in the meta-analysis). These same techniques were used to search for studies examining the relationship between dopamine administration and CBF in normotensive preterm infants. Only published studies were included in the meta-analysis.
Study selection
To be included in the meta-analysis, studies must have examined dopamine therapy for treatment of hypotension in the preterm infant, and contain sufficient information to calculate an effect size correlation. Studies examining normotensive preterm infants were included if CBF before and during dopamine administration was monitored. To address hypotheses 1 and 2, all studies examining dopamine therapy for the treatment of hypotension in preterm infants were metaanalytically examined. The outcome of interest was systemic blood pressure pre-and post-treatment with dopamine, and the relative efficacy of dopamine to other therapies for increasing blood pressure.
To address hypotheses 3 and 4, all studies examining CBF before and during dopamine administration in hypotensive and normotensive preterm infants were meta-analytically examined. The outcome of interest was an increase in CBF following dopamine administration, and the relative efficacy of dopamine to other therapies for increasing CBF. To address hypothesis 5, all studies examining adverse neurologic outcomes following dopamine administration in hypotensive preterm infants were meta-analytically examined. The outcome of interest was any adverse neurological event following dopamine administration, and the incidence of adverse neurological events associated with dopamine administration relative to other therapies for treatment of neonatal hypotension.
To allow for the greatest possible statistical power to detect relationships of interest, and to provide for the most informative analysis possible, inclusion of studies did not depend on the type of the study, and thus retrospective, prospective, observational and randomized placebo-controlled clinical trials were all included.
Data extraction
Standard meta-analytic techniques, including a random effects model and a fixed effects model, were used to calculate and combine the effect sizes from each study included in the metaanalysis. 14 The Pearson correlation coefficient r was used as the effect size indicator. The Pearson correlation coefficient r ranges from a strongly negative association À1.00, to a strongly positive association 1.00, with increasing lack of association as the value approaches 0.00. Traditionally, values of the effect size correlation are considered 'large' if >0.5, 'medium' if >0.3 and 'small' if >0.1. Many clinically important results of biomedical research have effect size r's that are extremely small. For the sake of comparison, the Salk vaccine trial had an effect size r ¼ 0.011. Although effect size indicators, such as the odds ratio, risk difference and relative risk are more commonly used in biomedical research than the Pearson correlation coefficient, there are several problematic issues inherent to their use. The most serious concern with the use of these indices is that very different phenomenological results can yield identical odds ratios, risk difference indices and relative risk indices. A complete discussion of the issues inherent to the use of the odds ratio, risk difference and relative risk is beyond the scope of this paper, and we refer the reader to other sources for a full discussion. 16, 17 Effect sizes were directly calculated from raw or descriptive data presented by studies whenever possible. In the event that these data were not presented, effect size estimates were obtained from test statistics or associated significance levels. A conservative approach was taken with studies, which did not present raw data, descriptive data or test statistics, and reported significance tests as 'not statistically significant' without providing a significance level. These studies were assigned a significance level of P one-tail ¼ 0.50, with an associated effect size r ¼ 0.00. This approach is standard meta-analytic technique. 16 When repeated-measures designs were used, and raw data were unavailable, calculations were performed based on the final time point provided.
Greater values of the effect size estimate r indicate greater increases in blood pressure and CBF and greater treatment success rate and therapy efficacy. Smaller values of r indicate a lower incidence of adverse neurologic outcome among study participants administered dopamine in comparison with other treatments.
Retrievability bias has been discussed as a potential source of bias in meta-analytic research. Following the basic principles of statistical significance testing, published research may represent the 5% of studies that obtained significant results because of type I error.
To address retrievability bias, the failsafe N associated with each significance test of the main effects computed in this meta-analysis is presented. 16 The failsafe N is a procedure based on the fixed effects meta-analytic model, and provides the number of studies with null results (P ¼ 0.50) that would have to be added to the meta-analysis in order to bring the results of the meta-analysis to a non-significant level (typically defined as P ¼ 0.05). The Failsafe N is symbolized by the letter 'k'. No assumptions other than homogeneity of variance, independence of sampling units, and normal distribution are required for the use of this technique.
For each hypothesis, a sensitivity analysis was performed to examine the effect of study methodology on measured associations. The sensitivity analysis examined measured associations after removing studies without random assignment of participants to treatment groups.
Data were analyzed by manual calculation of effect size estimates and significance tests. Calculations were confirmed by the use of a statistical software package, SPSS for windows version 12.0 (IBM, Somers, NY, USA).
Results
Sample sizes, associated effect size estimates and methodological designs, for studies examining blood pressure increases and treatment success are presented in Table 1 . 4,8,9,13,18 -39 For studies using a case-control design or random assignment to therapy for hypotension, sample sizes and associated effect size estimates of the efficacy of dopamine therapy for increasing blood pressure in comparison with epinephrine, dobutamine, hydrocortisone, colloid or no therapy are presented in Table 2 . 4, 9, 13, 17, 18, 21, 22, [24] [25] [26] 28, 29, 31 Sample sizes and associated effect size estimates for studies examining CBF are presented in Table 3 . 8, 9, 18, 25, 29, 36, 37, 40 Sample sizes and associated effect size estimates for studies examining adverse neurologic outcome are presented in Table 4 . 13, 19, 20, 24, 26, 28, 30, 32 Results are reported for the random effects meta-analytic approach, in which individual studies are considered the sampling unit, allowing generalization to other studies of the population from which this set of studies can be considered a sample, and the fixed effects meta-analytic approach, in which participants in the individual studies are considered the sampling unit. Random effects models were used to examine overall effects of dopamine administration, while fixed effects models were used to examine pairwise comparisons of dopamine administration with administration of dobutamine, hydrocortisone, epinephrine, colloid or placebo.
Hypothesis 1 'Dopamine administration significantly increases blood pressure in the hypotensive preterm infant. ' To examine hypothesis 1, 26 studies (N ¼ 376) investigating the effect of dopamine on hypotension were identified and included in the meta-analysis. Twelve studies (N ¼ 163) examined mean arterial pressure. Eight studies (N ¼ 142) examined systolic pressure. Twelve studies (N ¼ 235) examined treatment success (most often defined as an increase in blood pressure to age-appropriate levels).
Random effects. Random effects meta-analysis found dopamine therapy to be significantly associated with increases in mean 
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Abbreviation: Efficacy, overall therapy efficacy. r efficacy ¼ effect size estimates of overall therapy efficacy (the greater the number the greater the overall therapy efficacy of dopamine relative to comparison group). Fixed effects. The number of new or unretrieved studies averaging null results required to increase the overall P to 0.05 is k ¼ 434 for mean arterial pressure increase, k ¼ 123 for systolic blood pressure and k ¼ 725 for treatment success. Sensitivity analysis was performed including only studies using random assignment to treatment groups, again finding dopamine therapy to be significantly associated with increases in mean arterial blood pressure (three studies; N ¼ 51; r ¼ 0.83, 95% CI ¼ 0.71 to 0.90) and systolic blood pressure (two studies; N ¼ 45; r ¼ 0.85, 95% CI ¼ 0.74 to 0.92). Also, a significant association was again found between dopamine administration and treatment success (12 studies; N ¼ 182; r ¼ 1.00, 95% CI ¼ 1.00 to 1.00).
Hypothesis 2 'The efficacy of dopamine administration in increasing blood pressure is greater than the efficacy of other forms of therapy for the treatment of hypotension in the preterm infant. ' To examine hypothesis 2, a composite outcome variable was formed by combining mean arterial pressure, systolic blood pressure and treatment success. This approach was taken given the varying measures used by studies to operationalize the efficacy of dopamine therapy. As mean blood pressure is the most informative measure of blood pressure, this variable was given preference in forming the composite variable, followed by systolic blood pressure, and finally, treatment success. In other words, when it was possible to calculate an effect size estimate based on mean blood pressure, this value was used as the effect size associated with a given study.
To compare the efficacy of dopamine administration with other therapies for treatment of hypotension in the preterm infant, 6 independent studies (N ¼ 190) examining mean arterial pressure, 1 independent study (N ¼ 40) examining systolic blood pressure, and 10 independent studies (N ¼ 367) examining treatment success were identified and included in the meta-analysis. Following the formation of the composite variable, effect sizes were available for 14 studies. One study was identified that used an empty control group design, and this study did not find a difference in overall therapy efficacy between dopamine administration and no therapy (one study; N ¼ 21; r ¼ 0.00; 95% CI ¼ À0.43 to 0.43).
The number of new or unretrieved studies averaging null results required to increase the overall P to 0.05 is k ¼ 36 for the comparison of dopamine to dobutamine, k ¼ 16 for the comparison of dopamine with colloid and k ¼ 1 for the comparison of dopamine to hydrocortisone.
Sensitivity analysis was performed only in studies using random assignment to treatment groups. Following exclusion of one study from the analysis, dopamine administration was again associated with a significantly greater overall therapy efficacy than dobutamine (six studies; N ¼ 209; r ¼ 0.23, 95% CI ¼ 0.12 to 0.34).
Following exclusion of one study from the analysis, dopamine administration was again associated with a significantly greater overall therapy efficacy than colloid (one study; N ¼ 39; r ¼ 0.47, 95% CI ¼ 0.18 to 0.69).
For the comparison of dopamine administration with epinephrine, hydrocortisone and no therapy, all studies included in the meta-analysis used random assignment to treatment groups, and sensitivity analysis was not performed.
Hypothesis 3
'Dopamine administration is associated with increased CBF in the hypotensive preterm infant.' 
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To examine hypotheses 3, five independent studies (N ¼ 75) investigating the effect of dopamine on CBF in hypotensive preterm infants were identified and included in the meta-analysis.
Random effects. A random effects meta-analytic model found dopamine administration to be associated with increases in CBF in hypotensive preterm infants (five studies; N ¼ 75; r ¼ 0.36; 95% CI ¼ À0.059 to 0.67).
Fixed effects
The number of new or unretrieved studies averaging null results required to increase the overall P to 0.05 is k ¼ 14 for the increase in CBF associated with dopamine administration.
One study was identified comparing cerebral hemodynamics following dopamine administration to another therapy. This study found no significant difference in cerebral blood velocity following dopamine administration in comparison with epinephrine administration (one study; N ¼ 59; r ¼ 0.00; 95% CI ¼ À0.26 to 0.26).
Sensitivity analysis was performed including only studies using random assignment to treatment groups, again finding dopamine therapy to be significantly associated with increases in mean arterial blood pressure (three studies; N ¼ 51; r ¼ 0.83, 95% CI ¼ 0.71 to 0.90) and systolic blood pressure (two studies; N ¼ 45; r ¼ 0.85, 95% CI ¼ 0.74 to 0.92). A significant association was again found between dopamine administration and treatment success (12 studies; N ¼ 182; r ¼ 1.00, 95% CI ¼ 1.00 to 1.00).
Sensitivity analysis was not performed as all studies employed non-random assignment to treatment groups.
Hypothesis 4
'The increase in CBF following dopamine administration is greater in the hypotensive preterm infant than in the normotensive preterm infant because of the differences in the functional integrity of CBF autoregulation between the two groups. ' To examine hypothesis 4, three independent studies (N ¼ 78) investigating the effect of dopamine on CBF in normotensive preterm infants were identified and included in the meta-analysis.
Random effects. A random effects model found that dopamine administration in normotensive infants was not associated with a significant increase in CBF (three studies; N ¼ 78; r ¼ 0.022; 95% CI ¼ À0.074 to 0.12).
Fixed effects. In concordance with the random effects model, a fixed effects model found that dopamine administration in normotensive infants was not associated with a significant increase in CBF (three studies; N ¼ 78; r ¼ 0.031; 95% CI ¼ À0.20 to 0.26).
The increase in CBF following dopamine administration was greater in hypotensive preterm infants than in normotensive preterm infants (eight studies; N ¼ 153; r ¼ 0.16; 95% CI ¼ À0.0080 to 0.32).
A failsafe N analysis was not conducted, as this procedure is reserved for examining main effects of treatments rather than moderating variables.
A sensitivity analysis was not performed as all studies examining CBF following dopamine administration used non-random assignment to treatment groups.
Hypothesis 5
'Dopamine administration is associated with an incidence of adverse neurological outcomes similar to the incidence of adverse neurological outcomes associated with other forms of therapy for hypotension in the preterm infant.'
To examine hypothesis 5, seven independent studies (N ¼ 331) investigating the association of dopamine administration and alternative therapies for the treatment of hypotension with adverse neurological outcomes were identified and included in the meta-analysis. A composite variable, labeled 'adverse neurological outcomes', was formed by combining periventricular leukomalacia, periventricular hemorrhage, intraventricular hemorrhage and neurodevelopmental delay. This composite variable was formed to increase the statistical power to detect relationships between therapeutic modalities and adverse neurological outcomes.
Fixed effects. A fixed effects meta-analytic model was used to compare adverse neurological outcomes following dopamine administration with each of the other forms of therapy included in the meta-analysis.
Dopamine was associated with a trend toward a lower incidence of adverse neurological outcome than dobutamine (three studies; N ¼ 118; r ¼ À0.13; 95% CI ¼ À0.31 to 0.059), however, this comparison did not reach the traditionally accepted level of statistical significance (P one-tailed ¼ 0.10).
No statistically significant differences in adverse neurological outcome were found between dopamine administration and epinephrine (two studies; N ¼ 46; r ¼ 0.06; 95% CI ¼ À0.23 to 0.34), colloid (two studies; N ¼ 80; r ¼ 0.0070; 95% CI ¼ À0.22 to 0.23) or hydrocortisone administration (one study; N ¼ 40; r ¼ À0.10; 95% CI ¼ À0.40 to 0.22).
As no analyses reached the traditional level of statistical significance, failsafe N analysis was not performed.
A sensitivity analysis was not performed as all studies examining adverse neurological outcomes used random assignment to treatment groups.
Discussion
Results of this meta-analysis support hypothesis 1, finding that dopamine administration is associated with significant increases in blood pressure in the hypotensive preterm infant. Results of Dopamine, hypotension and cerebral hemodynamics S Sassano-Higgins et al this meta-analysis also support hypothesis 2, finding that, with the exception of epinephrine, dopamine administration are associated with greater increases in blood pressure than other therapies used to treat hypotension in the preterm infant. Hypotheses 3 and 4 were supported as well, because dopamine administration was associated with increases in CBF in hypotensive preterm infants, and with greater increases in CBF in hypotensive than in normotensive preterm infants. Finally, the findings also support hypothesis 5, as the incidence of adverse neurological outcome in dopamine-treated hypotensive preterm infants was not different from that associated with alternative therapies. The variance of effect size estimates for the measured associations was small, but possibly clinically important, and examination of variables moderating the measured associations is subject for future research. Although statistical power is increased by inclusion of studies using non-random assignment to treatment groups, the inclusion of these studies may introduce uncontrolled bias. To address this issue, sensitivity analysis was performed. Following exclusion of non-randomized studies from the analysis, dopamine administration remained associated with significant increases in mean arterial pressure, systolic blood pressure and treatment success, and significantly greater overall therapy efficacy than dobutamine, colloid and hydrocortisone. As all studies examining CBF in hypotensive neonates used non-random assignment to treatment groups, this is an area that warrants further research to establish the efficacy of dopamine administration for increasing CBF. As all studies examining adverse neurological outcome used random assignment to treatment groups, the safety of dopamine relative to other therapies was not altered by exclusion of non-randomized studies.
Dopamine administration appears to be an effective therapy to increase blood pressure and CBF in the preterm infant with hypotension. The increase in blood pressure following dopamine administration is a robust relationship, with an extremely large tolerance for unpublished, or future, null results.
Comparisons of the overall efficacy of dopamine therapy to other therapies, in terms of increasing blood pressure, are less robust. These findings are nonetheless noteworthy, and suggest that, with the exception of epinephrine, dopamine may be the most efficacious therapy for increasing blood pressure in hypotensive preterm infants.
Dopamine administration was found to be associated with increases in CBF in hypotensive preterm infants. This relationship was less robust than the association between dopamine administration and the drug-associated increases in blood pressure. Nonetheless, the effect size estimate found in this study is the best estimate available to date of the effect of dopamine on increasing CBF in the hypotensive preterm infant. Further research is required though to fully establish the efficacy of dopamine administration for increasing CBF in the hypotensive preterm infant. Of particular interest would be studies comparing CBF following dopamine administration with other forms of therapy.
Of note is that one study included in the meta-analysis, 29 reported a transient increase in CBF following dopamine administration with CBF returning to a baseline mean value within 50 to 90 min. According to the design of this meta-analysis, it was pre-determined that all measurements would be calculated based on the final reported time-points. The study in question 29 was calculated to have an effect size of zero, which likely underestimates the true effectiveness of dopamine efficacy in increasing CBF. The findings of this study also underscore the likelihood that increases in CBF are dose dependent.
The finding that the increases in CBF following dopamine administration were greater in 'hypotensive' than 'normotensive' preterm infants suggests that dopamine does not exert a selective vasodilatory effect in the cerebral circulation 40 and that the blood pressure of infants treated for hypotension was below the lower elbow of the CBF autoregulatory curve. Thus, these patients met the hemodynamic criteria of having systemic hypotension. 41 However, as preterm neonates may present with compromised CBF autoregulation, this notion has to be viewed with caution. Indeed, compromised CBF autoregulation may develop because of earlier hypoxic and/or hypotensive insults, abnormal carbon dioxide levels, 42 acid-base balance abnormalities, extreme immaturity and the underlying pathological conditions. 43 It needs to also be emphasized that the results of this study provide only preliminary evidence that the dopamine-induced increase in blood pressure is associated with a different pattern of changes in CBF between 'hypotensive' than 'normotensive' preterm neonates. Although this meta-analysis provides the most current analysis of the available findings, none of the studies included employed designs directly comparing the pattern of CBF response between the two patient populations. Given the lack of direct comparisons between 'hypotensive' and 'normotensive' patients, and the small number of studies providing data on the changes in CBF, it is possible that this relationship may undergo modification as more research becomes available.
As dopamine is the most commonly used vasopressor/inotrope for the treatment of hypotension in the preterm infant, the finding that dopamine is not associated with a significantly greater incidence of adverse neurological outcomes than other therapies is at least encouraging. As a matter of fact, dopamine administration was found to be associated with a potentially clinically relevant, although statistically nonsignificant, lower incidence of adverse neurological outcomes than dobutamine.
However, it is important to note that statistical significance testing can only establish relationships, and cannot prove the lack of a relationship. That is, although significance testing did not show dopamine administration to be associated with a greater incidence of adverse neurological outcomes than other therapies, it is not possible to unequivocally state from the results of non-statistically significant tests that dopamine administration is less harmful to the brain of the preterm infant than administration of alternative therapies. Although difficult for ethical and logistical reasons, more research is needed to determine the long-term neurodevelopmental impact of different approaches to the treatment of neonatal cardiovascular compromise in the transitional period, including withholding treatment in patients with hypotension but without clinical or laboratory evidence of cardiovascular compromise (permissive hypotension 14 ) , or provision of volume-and pharmacotherapy. Therefore, the findings of this study should be carefully evaluated when assessing their clinical relevance and, as long as evidence from appropriately designed clinical trials is not available, vasoactive amines should be carefully titrated to a reasonably chosen optimum cardiovascular response to minimize the potentially harmful sudden changes in blood pressure and organ blood flow that can be associated with the administration of these vasoactive medications. 5, 11, 13, 29 Finally, to increase statistical power, the current meta-analysis was performed after forming a composite variable for adverse neurological outcome. Thus, the relative contribution of each of the variables was not examined, and their individual association with therapies for the treatment of hypotension remains an area for future research.
In summary, with the exception of epinephrine, dopamine administration is more effective at raising blood pressure than the other treatment modalities in the preterm infant. The increase in CBF following dopamine administration was found to be greater in hypotensive than normotensive preterm infants, suggesting the presence of pressure-passive CBF in the hypotensive neonate. Although more research is necessary to establish the effects of dopamine administration on the developing brain, the incidence of adverse neurological effects following dopamine administration does not appear to be different from that seen with other common treatments for hypotension in the preterm neonate.
